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Abstract
Aim—Nonadherent individuals are the most likely to avoid participating in research studies, thus
limiting potential opportunities to develop evidence-based approaches for adherence enhancement.
This mixed-method analysis evaluated factors related to adherence among 20 poorly adherent
community mental health clinic patients with bipolar disorder (BD).
Methods—Illness experience was evaluated with qualitative interview. Quantitative assessments
measured symptoms (Hamilton Depression Rating Scale, Young Mania Rating Scale, Brief
Psychiatric Rating Scale), adherence behavior, and treatment attitudes. Poor adherence was
defined as missing 30% or more of medication.
Results—Minorities (80%), unmarried individuals (95%), and those with substance abuse (65%)
predominated in this nonadherent group of patients with BD. Individuals were substantially
depressed (mean Hamilton Depression Rating Scale, 19.2), had at least some manic symptoms
(mean Young Mania Rating Scale, 13.6), and had moderate psychopathology (mean Brief
Psychiatric Rating Scale, 41.2). Rates of missed medications were 41% to 43%. Forgetting to take
medications was the top reason for nonadherence (55%), followed by side effects (20%).
Disorganized home environments (30%), concern regarding having to take long-term medications
(25%) or fear of side effects (25%), and insufficient information regarding BD (35%) were
relatively common. Almost one third of patients had individuals in their core social network who
specifically advised against medication. Access problems included difficulty paying for
medications among more than half of patients. Interestingly, patients reported good relationships
with their providers.
Conclusions—Forgetting to take medication and problems with side effects are primary drivers
of nonadherence. Lack of medication routines, unsupportive social networks, insufficient illness
knowledge, and treatment access problems may likewise affect overall adherence. Complementary
quantitative and qualitative data collection can identify reasons for nonadherence and may inform
specific clinical approaches to enhance adherence.
© 2011 Elsevier Inc. All rights reserved.
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1. Introduction
Psychotropic medications are a cornerstone of treatment for individuals with bipolar
disorder (BD); however, nonadherence with prescribed medication is pervasive and is
associated with negative outcomes, such as illness relapse [1,2]. Clinically relevant BD
nonadherence has been defined as missing 20% to 30% or more of prescribed medication
[3,4]. Two large Veterans Administration (VA) studies on treatment adherence of patients
with bipolar disorder found that 46% to 48% of patients with bipolar disorder miss at least
20% of prescribed maintenance medication [5,6]. In these studies, predictors for missing at
least 20% of prescribed BD medication treatments were younger age, unmarried status,
minority ethnicity, and comorbid substance abuse or posttraumatic stress disorder [5,6].
Other predictors of treatment nonadherence in BD include male sex, poor social support,
inadequate knowledge of BD, and health beliefs that are not consistent with maintaining
long-term medication prophylaxis [3,7–9].
Most studies have not focused specifically on nonadherent populations with bipolar
disorder, and few studies have further addressed these individuals’ perceptions of illness and
treatment in relation to medication treatment adherence [7,8]. Patient-focused qualitative
methods may shed valuable insights on patients’ beliefs about treatment [10]. Unless one
understands why an individual may or may not adhere to prescribed BD medication
treatment, it is difficult to develop interventions that address nonadherence. In addition,
focusing on patients with BD who are known to be poorly adherent may provide invaluable
information toward intervention development to improve care for BD subpopulations at
greatest risk for poor health outcomes.
This is a mixed-method (qualitative and quantitative) characterization of reasons for
treatment nonadherence among individuals known to be poorly adherent with medication
treatment. The study used a standardized adherence cutoff, and all participants with BD
were receiving care in a public sector mental health setting.
2. Methods
2.1. Population and procedures
Participants had type I or II BD confirmed by the Mini-International Neuropsychiatric
Interview (MINI) [11], were receiving treatment at a community mental health clinic
(CMHC), and were known to be poorly adherent. Poor adherence was defined as self-
reporting missing 30% or more of medication within either the past week or past month
using the Tablets Routine Questionnaire [3,12]. Adherence was also identified via pill
counts. Additional study inclusion criteria were BD for at least 2 years duration and
treatment with an antipsychotic agent or a mood stabilizer for at least 6 months. The study
was approved by the local institutional review board.
2.2. Measures
Study participants were evaluated using the Subjective Experience of Medication Interview
Treatment Adherence Bipolar Disorder Version (SEMI TAD BD), a qualitative interview
modified from the original SEMI [13]. The SEMI TAD BD focuses on (1) patient factors
(explanatory model of illness, comfort with fund of knowledge, patterns of treatment
adherence, stance toward medications in general, self-management behaviors, self-
medications, sociability patterns with respect to bipolarity, occupational factors, and cultural
factors), (2) environmental/social factors (home environment, social relations/psychosocial
supports, and negative social effects), (3) provider/system factors (perceived helpfulness and
communications with providers), (4) health beliefs (perceived illness severity, susceptibility
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to illness, and benefits of treatment), and (5) costs/burdens associated with treatment
(medication regimen burden, side effects, stigma, affordability, and care access).
Most items in the SEMI TAD BD can be answered with a short response, for example, “Did
you ever have difficulties with taking or remembering to take your medications in the past?”
The question is then expanded to query individuals who respond affirmatively to further
elaborate. At the conclusion of the semistructured interview, participants were asked to
provide their opinion on their main reason for treatment nonadherence.
In addition to the SEMI TAD BD, quantitative assessments of bipolar symptoms and
psychopathology (Hamilton Depression Rating Scale [HAMD] [14], Young Mania Rating
Scale [YMRS] [15], Brief Psychiatric Rating Scale [BPRS] [16], Clinical Global Impression
for use in Bipolar Disorder [17]) and key attitudinal standardized measures of bipolar
treatment including the Attitude toward Mood Stabilizers Questionnaire (AMSQ) [3,18], the
Drug Attitude Inventory (DAI) [19], and the Rating of Medication Influences (ROMI) [20]
were conducted.
The AMSQ is a modification of the Lithium Attitudes Questionnaire [21], which evaluates
an individual’s attitudes toward mood-stabilizing medication [3,18]. The AMSQ has 7
subscales representing key attitudinal domains including (1) opposition to prophylaxis, (2)
denial of therapeutic effectiveness, (3) fear of side effects, (4) difficulty with medication
routines, (5) denial of illness severity, (6) negative attitude toward drugs in general, and (7)
lack of information about mood stabilizers [3,18,21]. Higher scores on each subscale
represent more negative attitudes. The DAI is used to measure attitudes toward medication
among individuals with serious mental illness [19]. The ROMI is a measure of attitudes
toward medication treatment, which has been demonstrated to identify health beliefs and key
reasons for medication nonadherence [1,18,22]. The ROMI contains 19 items that directly
inquire about influences leading to adherence (9 items) and those leading to nonadherence
(10 items).
2.3. Data analysis
Descriptive analysis was conducted using the demographic/clinical information and
quantitative findings. The SEMI TAD BD was transcribed from the audiotapes in its entirety
and entered into a software program, Atlas.ti (Scientific Software Development GmbH)
[23], to be able to code and analyze the qualitative data systematically [24,25]. Narrative
data from the SEMI TAD BD were coded into discrete themes and evaluated across
participants for each thematic domain. Multirater consensus coding was conducted on an
ongoing basis by the research team to continually refine and improve coding accuracy. For
this analysis, 2 independent raters coded each SEMI question with resulting κ values in each
domain ranging from 0.63 to 1.0 (environmental/social factors), 0.6 to 1.0 (patient factors
related to illness experience), 0.69 to 1.0 (health belief factors), 1.0 all scores (provider/
system factors), and 0.63 to 1.0 (costs/burden factors). The median κ score for each SEMI
question was 1.0 (perfect agreement between raters).
3. Results
3.1. Quantitative findings
Table 1 illustrates demographic and standardized rating scale characteristics. Minorities
(80%, n = 16), unmarried individuals (95%, n = 19), and those with substance abuse/use
predominated. Substance abuse/use identification (65%, n = 13) was derived from the MINI,
SEMI TAD BD, and ROMI to minimize substance abuse underreporting.
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Individuals were substantially depressed (mean 17-item HAMD, 19.2; range, 12–28), had at
least some manic symptoms (mean YMRS, 13.6; range, 3–35), and had moderate
psychopathology (mean BPRS, 41.2; range, 29–60). Rates of missing prescribed
medications were in the order of 41% to 43%. The AMSQ, DAI, and ROMI found generally
negative attitudes toward medication and limited insight into illness.
The AMSQ subscales, mean values, and average item-response values per subscale are
listed in Table 1. The highest average item-response values (more negative attitudes toward
medication) were the subscales addressing difficulty with medication routines, denial of
illness severity, and fear of medication side effects. Fig. 1 identifies the individual AMSQ
item scoring, in terms of mean item-response value, and indicates the items that in particular
have relatively high scores (more negative attitudes).
3.2. Qualitative findings
3.2.1. Self-identified primary reasons for medication nonadherence—Consistent
with findings from the quantitative measures, forgetting to take medications was the top
self-reported reason for nonadherence (55%). On the qualitative assessment, patients
identified side effects (20%) as the second most common reason for nonadherence. Other
reasons included not wishing to take medications for the rest of one’s life and desire to
experience manic symptoms.
3.2.2. Environmental/Social factors—Although 55% (n = 11) of individuals described
their living place as easygoing, almost one third (n = 3) described their homes as tense,
unpleasant, or disorganized (n = 6). Social contact was deemed inadequate by 35% (n = 7)
of participants, and 35% (n = 7) did not feel there were individuals in their social network
with whom they could talk freely about their illness. Half of the individuals (n = 10) noted
that there was someone in their support network who reminded them to take medications,
but almost one third (n = 6) had individuals who specifically advised against medications.
One participant described her experience with being told not to take medications, “My
mother said I should think about it and try to use…reason and creativity instead of the
medication.”
Another participant noted, “Some people don’t believe in them [medication] and they voice
that opinion.”
3.2.3. Patient factors related to illness experience—Just over one third (n = 7) of
individuals felt that they did not have enough information about BD. Most (70%, n = 14) of
the individuals noted that they had difficulty taking or remembering to take medications and
at times did not believe in taking pills (65%, n = 13).
One participant described forgetting her medications, “I don’t say I am not going to take it
today because I feel good. It’s just because I forget to take it.”
Another participant described how ambivalence regarding need for medication and
forgetting to take medications both contributed to her nonadherence, “One thing was I was
trying to see if I could go without taking them, but the other thing was that it’s not that I
decide not to take them—well, maybe I do.…I don’t remember if I took them, so rather than
double-take them, I’ll just do without them…”
Another participant noted that her twice-daily medication regimen contributed to difficulty
remembering, “It would be better for me to be able to take once a day than to remember to
take twice a day and which ones to take twice a day.”
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Individuals had a variety of methods to help them remember to take medications, including
putting them in a consistent/specific place (35%, n = 7), labeling or writing reminders,
taking medications at a consistent/specific time (15%, n = 3), or some combinations of
multiple methods (5%, n = 1). Two thirds of individuals (65%, n = 13) reported that religion
or spirituality was important to their coping with illness. Alcohol was used by 45% (n = 9),
and recreational drugs were used by 25% (n = 5), with slightly differing proportions of
individuals admitting to using/abusing substances depending on the format of the interview
questions.
3.2.4. Health belief factors—Most individuals perceived that their BD treatments had
helpful effects on overall mood (75%, n = 15,), functional level (70%, n = 14), and stress
levels (80%, n = 16), although individuals also noted problems with their medications, such
as not liking having to take medications in the first place (25%, n = 5) or the possibility of
long-term or unknown side effects (25%, n = 5). More than half (55%, n = 11) reported that
they did not feel like they had any personal power or control over their illness.
One participant described how she viewed the effects of medication, “I feel…kind of foggy
and cloudy, but the advantages of taking them is better than the set-backs so it’s
worthwhile.”
3.2.5. Provider/System factors—Nearly all individuals reported a good relationship
with their treatment provider (95%, n = 19), and most (75%, n = 15) had no difficulty
communicating with their provider.
3.2.6. Costs/Burdens—Individuals encountered a variety of barriers to taking
medications, including a perception that they had an excessive number of prescribed
medications (25%, n = 5), an excessive dose of medications (20%, n = 4), and access
problems including inability to pay for medications (60%, n = 12) or get transportation to
appointments (35%, n = 7). Burdensome side effects included multiple physical complaints
(25%, n = 5) or specific problems, such as drowsiness (15%, n = 3).
One participant described how side effects impacted her general health and her relationships
with others, “I don’t like the side effects. I don’t like how people judge me because I’m on
medication and I’ve gained over 100 lb in less than a year.”
Finally, the group was evenly split among those who believed that mental illness is
associated with stigma (n = 9, 45%) and those who did not feel there was stigma related to
having a mental illness (n = 9, 40%). Only half of the group (n = 10) noted that they
routinely shared information regarding their mental diagnosis with others.
One participant described the impact of stigma, “I’m kind of embarrassed about it because a
lot of people get afraid.”
4. Discussion
This mixed-method analysis evaluated patients with BD receiving treatment in a public
sector mental health setting using a standardized adherence cutoff. Quantitative analysis
suggested that difficulties with medication routines, worry about medication side effects,
and denial of illness severity were the most important contributors to negative attitudes
toward BD medications. Qualitative findings characterized the strong effect of forgetting on
nonadherence, the impact of such side effects as sedation and weight gain, and belief that
medications were not really needed. Although the quantitative results provided information
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on general constructs related to nonadherence, qualitative findings provided perspective on
specific processes leading to nonadherence.
Consistent with the published literature on clinical characteristics that predict treatment
nonadherence, minorities and individuals with less social support predominated [6,7].
Individuals were generally at least moderately symptomatic with substantial manic and/or
depressive symptoms. Manic symptoms in particular have been noted to be associated with
treatment nonadherence in populations with bipolar disorder [26] and could have contributed
to some of the perceived denial of illness severity (or need for medications) seen in our
sample. Depression could have contributed to social isolation or lack of engagement in care
that precipitated or worsened nonadherence.
Standardized measures of adherence attitudes, such as the AMSQ and ROMI, can be helpful
in identifying patients with BD and groups of patients at risk for nonadherence, and it has
been suggested that use of multiple measures should be implemented given the various
factors that might contribute to adherence [4,27]. Reasons for adherence and reasons for
nonadherence as identified by separate subscales of the ROMI were relatively similar in our
sample, in contrast to what has been reported in adherent populations with bipolar disorder
[22], where there are more marked contrasts in reasons for adherence vs nonadherence
(advantage favoring adherence). Attitudes toward medications as measured by total mean
AMSQ scores in these poorly adherent patients with bipolar disorder were within the range
of total mean AMSQ scores (6.8–9.0) identified in other studies of poorly adherent
individuals with bipolar disorder [3,22].
Semistructured qualitative analysis provided further elaboration on factors identified in the
quantitative assessment as adherence barriers and identified some additional factors that are
potential facilitators or barriers to adherence. The qualitative information provided a
contextual description of adherence barriers upon which to formulate possible clinical
approaches that can enhance adherence in high-risk patients. Forgetting medications and
side effects were primary reasons for not taking prescribed medications. Home settings were
perceived by one third of individuals as tense or disorganized, whereas social networks were
perceived to be nonsupportive or even directly antagonistic to medication adherence.
Psychosocial interventions intended to enhance treatment adherence in bipolar populations
need to address individual/unique psychosocial needs [9,28]. The data from our nonadherent
sample suggest that special attention to establishing medication routines (for example,
identification of optimum strategies as to where medications are stored, when or how they
should be taken, and possibly use of technology-assisted devices) might be particularly
helpful. Education and engagement of significant others regarding need for medication
maintenance in the treatment of bipolar illness could potentially transform some treatment
adversaries into treatment allies. In other instances, where the social network is adamantly
opposed to medication treatment, the patient with BD might benefit from additional sources
that are supportive of pharmacotherapy, for example, consumer advocacy groups such as the
Depression and Bipolar Support Alliance [29].
One third of the sample did not feel that they knew enough about BD and BD treatment, and
this may have led to an underappreciation of the severity of illness. This emphasizes the
importance of psychoeducation, which is known to promote illness self-management
[30,31].
Most individuals in this sample had a variety of methods to try and cope with illness and
treatment, including spiritual approaches or self-medication with drugs or alcohol. This
suggests a strong role for integrating existing and/or available supports into the
pharmacological and psychotherapeutic treatment plan, including consideration of the
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individual’s spiritual orientation and facilitation of entry into concurrent substance abuse
treatment. Individuals who are resistant to or not yet ready to enter substance abuse
treatment might benefit from psychosocial approaches that address the negative effects of
substance abuse on treatment outcomes, especially when integrated in a provider-patient
relationship that includes regular and frequent contact [32,33].
Consistent with some other reports, many of these nonadherent individuals with BD did not
feel as though they had personal control over their illness [34]. Although most individuals
perceived medications as being helpful, with specific beneficial effects on mood, functional
status, and stress levels, this was balanced by concerns about current or potential problems.
Promoting health beliefs that support appropriate pharmacotherapy, empowering patients to
take control of their illness, and confronting inaccurate health beliefs via psychosocial
interventions could improve treatment adherence among individuals who feel powerless
with respect to their BD [30,35].
In spite of their nonadherence with prescribed medications, most individuals in the study
presented here noted that they had good relationships with the prescribing clinicians—these
patients liked their physicians but not the drugs their physicians prescribed. In contrast,
Zeber et al [32] have reported that medication adherence is related to therapeutic alliance,
with better adherence seen when clinicians regularly review progress and encourage contact.
The study did not collect information on specific clinician follow-up frequency for study
patients; however, the typical follow-up interval for patients at the CMHC is every 1 to 2
months.
It is possible that the nonadherent patients in our study sample represented a group of
individuals who had good therapeutic alliance but selectively elected to not take
recommended medications. The study did not also collect information on the providers, and
thus, it is not clear how candid the patients were with providers regarding their
nonadherence. It is possible that the mental health care providers of these individuals were
under the impression that their patients were fully adherent. It has been well demonstrated in
the psychiatric literature that clinicians’ assessments of treatment adherence are generally
poor. For example, a study of patients with schizophrenia demonstrated that technology-
assisted methods such as Medication Event Monitoring Systems (MEMS) classified 48% of
schizophrenic patients as nonadherent, whereas clinician ratings failed to classify even one
patient as nonadherent [36].
Finally, there were numerous factors that poorly adherent individuals identified as barriers to
treatment, which are known to be associated with suboptimal treatment adherence [37].
Medication side effects are a major factor that affects general health, quality of life, and
relationships with others. It is critical that clinicians actively seek input from patients on
perceived side effects and the relative burden of side effects.
A major problem for nearly two thirds of individuals was inability to pay for medications at
least some of the time. Difficulty in paying for medications might have been related to the
high rate of unemployment (40%), which could be associated with limited financial
resources and/or lack of health insurance. In addition, although the study site CMHC was on
a public bus line and had evening and weekend hours, accessing transportation to clinic
appointments was a problem for one third of the group. Other barriers to treatment involved
perceived burden of number or amounts of pills prescribed.
Limitations of the study include small sample size, single-site study setting, and reliance on
imprecise measures of adherence (self-report and pill counts). Individuals at the most
extreme of treatment nonadherence (complete treatment dropouts) are not represented in this
sample. In addition, the qualitative assessment used in this study was developed based on
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the principle investigator’s preliminary data regarding barriers and facilitators to care as well
as the extant published literature. It is possible that a more comprehensive interview might
have yielded additional factors that motivate or impede treatment adherence. We believe that
a mixed-method approach, even with such a small sample as is presented here, strengthens
the validity of our findings. As noted by Sherman and Strang [38], in synthesizing
quantitative and qualitative results, numerical results are linked to patients’ experiences and
descriptions that articulate and communicate study findings more effectively.
5. Conclusions
Both quantitative measures, such as the AMSQ and ROMI, and qualitative approaches can
be useful in identifying nonadherence and reasons for nonadherence.
Poorly adherent patients with BD identify forgetting to take medication and problems with
side effects as primary drivers of nonadherence. However, personal, sociocultural, and
economic factors may likewise affect overall adherence.
Potential approaches to improve adherence among patients with BD include measures to
provide additional structure to the home setting, medication dosing simplification,
technology-assisted prompts, education/intervention with family members, interaction with
spiritual advisors, facilitation of substance abuse treatment, psychoeducation on BD and BD
treatments, and preemptive and candid discussion between providers and patients regarding
expected side effects from medications and how these might be best managed.
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Fig. 1.
The AMSQ item mean scores among poorly adherent bipolar patients. Higher mean scores
mean greater opposition/negative attitudes toward taking prescribed medication treatment
for bipolar disorder.
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Table 1
Clinical characteristics of nonadherent patients with BD
Frequency, n (%) Mean (median) SD Range
Age 37 (36.5) 12.14 18–59
Sex
 Female 14 (70)
Race
 Euro-American 4 (20)
 African American 14 (70)
 American Indian/Native American 1 (5)
 Asian 1 (5)
Marital status
 Single 13 (65)
 Married 1 (5)
 Separated 1 (5)
 Divorced 5 (25)
Education (y) 13 (12.0) 2.12 9–16
Occupation
 Full time 4 (20)
 Part time 2 (10)
 Unemployed 8 (40)
 Other 6 (30)
History of sexual abuse 12 (60)
Substance abuse/dependence (current)a 9 (45)
Bipolar type
 I 13 (65)
 II 7 (35)
HAMD-17 19.20 (18.5) 5.1 12–28
YMRS 13.6 (14.5) 7.28 3–35
BPRS 41.2 (40) 8.06 29–60
CGI-BP
 Mania 3.8 (4.0) 1.19 2–7
 Depression 4.7 (5.0) 0.98 2–7
 Overall bipolar illness 4.4 (4.0) 0.59 4–6
AMSQ total 8.3 (8.0) 4.13 2–16
Subscales mean (average per itemb)
Opposition to prophylaxis 1.35 (0.34) 1.35 0–4
Denial of therapeutic effectiveness 0.40 (0.20) 0.68 0–2
Fear of side effects 1.00 (0.50) 0.73 0–2
Difficulty with medication routines 2.65 (0.66) 1.23 0–4
Denial of illness severity 1.65 (0.55) 0.88 0–3
Negative attitude toward drugs in general 0.95 (0.32) 0.76 0–2
Compr Psychiatry. Author manuscript; available in PMC 2011 July 21.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Sajatovic et al. Page 13
Frequency, n (%) Mean (median) SD Range
Lack of information about mood stabilizers 0.30 (0.30) 0.47 0–1
DAI 4.61 (4.0) 2.78 0–9
Pill count, % missed 40.86% 30.66 7–100
TRQ
 Past month 41% 17.84 13–100
 Past week 43% 17.43 14–100
ROMI
 Adherence 16.25 (16.5) 3.83 5–22
 Nonadherence 11.95 (12.5) 3.96 3–21
DAI indicates Drug Attitude Inventory (10-item version, scale calibrated 0–10 with 10 being more positive attitudes); HAMD-17, Hamilton
Depression Rating Scale, 17-item version; CGI-BP, Clinical Global Impression for use in Bipolar Disorder; TRQ, Tablets Routine Questionnaire,
% of pills missed in last month or week as noted; Pill count, adherence to medication determined by pill count (last month).
a
As defined by the MINI.
b
AMSQ subscales have varying numbers of items.
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